Highwise Health
U.S.

FDA Approved Generic Version of Everolimus Tablets

Patients with cancer may soon have more treatment access with this generic version of Afinitor Disperz.

Updated on Sept. 23, 2026 in Cancer

Isometric editorial illustration of a glass beaker and a geometric molecular model, representing the approval of a generic cancer drug.
The FDA approved a generic version of Everolimus tablets, a kinase inhibitor used to slow the growth of cancer cells, aiming to improve treatment access. AI Illustration. Upload story photo >

Live Poll

Does the approval of generic drugs play a vital role in reducing your healthcare costs?

The FDA recently approved an Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension. This generic version of Afinitor Disperz will be available in 2mg, 3mg, and 5mg dosages.

Why it matters

Generic drug approvals are intended to increase access to treatments and potentially lower costs for patients. This development introduces a generic competitor into a market that saw $123 million in annual sales as of July 2026.

The FDA approval follows an Abbreviated New Drug Application submitted by ANI Pharmaceuticals. The tablets serve as a generic equivalent to Afinitor Disperz, though long-term clinical equivalency studies are not detailed here.

The players

FDA

The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products.

ANI Pharmaceuticals

A biopharmaceutical company based in Princeton, N.J., that develops and manufactures generic and branded pharmaceutical products.

The details

Everolimus is a kinase inhibitor that works by blocking the mTOR pathway, a protein complex that signals cells to grow and divide. By inhibiting this pathway, the drug can slow the proliferation of cancer cells. This generic formulation provides the same active ingredients in the same dosages as the reference product.

Timeline

  1. July 2026 was the period used for the reported $123 million in annual U.S. sales.

  2. September 23, 2026, marks the official announcement of the FDA approval.

Health Landscape

The market for Afinitor Disperz has remained established, with $123 million in annual sales recorded as of July 2026. This generic approval aligns with broader efforts to introduce competition to specialized oncology treatments.

Patients currently taking Afinitor Disperz may wish to discuss the availability and potential cost benefits of this generic version with their healthcare provider. It is important to confirm with a pharmacist or physician whether a generic substitution is appropriate for your specific treatment plan.

The takeaway

Generic approvals help increase the variety of available treatment options for patients managing complex health conditions. Always consult your oncology team before making any changes to your prescribed medication regimen.

Further reading

To learn more about how new developments in oncology affect care, visit Cancer.

Live Poll

Does the approval of generic drugs play a vital role in reducing your healthcare costs?